Award

Targeting BDNF signaling for postmenopausal brain health

Description: Females are at the epicenter of Alzheimer's disease (AD), with a 1 in 6 risk of developing the disease at age 65 compared to 1 in 11 for males. In fact, female sex is the second greatest risk factor for late-onset AD, second only to the aging process itself. Despite this, most research focuses on AD in males, and we do not fully understand why females are at a higher risk of AD. The loss of estrogen that females experience with menopause may be a contributing factor. Brain derived neurotrophic factor (BDNF) is known as a brain fertilizer because it helps maintain healthy brain cells, as well as grow new ones. BDNF is lower in patients with AD and is also lower in post-menopausal females. Our lab has made direct connections between BDNF content and a hallmark marker of AD. We have shown that BDNF can reduce the production of small proteins called amyloid-beta proteins. This is important because with AD these proteins build-up, stick together, and result in plaques that are bad for brain health. Our work aims to find ways to increase BDNF signaling and reduce these proteins. The purpose of this proposal is to target BDNF signaling in a female post-menopausal mouse model to reduce these proteins, improve memory, and maintain brain health. We will treat these mice with drugs that activate BDNF signaling. This work will highlight the potential for targeting BDNF to reduce AD risk in a post-menopausal model. To further characterize differences in male and female brains and enhance the translatability of our work, we will also examine these proteins in post-mortem human brain samples from male and female patients diagnosed with and without AD. These results will provide a much-needed understanding of sex differences that exist in the brain. Elucidating sex differences is instrumental in the development of a 'precision medicine' approach to support brain health. In using two different models we can look at biological markers, behavioural changes, and memory improvements.
Amount: CA$130,000
Funding type: research
Funder scheme: Catalyst Grant:National Women's Health Research Initiative: Innovation Fund - Biomedical Discovery Grants
Start date: 2024-02-01
End date: 2025-01-31
Institutions: Brock University, Brock University (Ontario)
Funded outputs count: 0
Funder award ID: 191320_1
OpenAlex ID: G4825613410